FDA updates its guidance, potentially enabling broader adoption of LLM-based clinical decision support software in radiology.
Key Details
- 1FDA released updated guidance on regulating clinical decision-support (CDS) software as a medical device in January 2024.
- 2The new guidance clarifies that certain LLM and CDS tools that do not directly analyze images may be exempt from device regulation if they meet four specific criteria.
- 3Previously, tools generating diagnostic text recommendations or risk predictions were typically regulated as medical devices.
- 4The updated interpretation may open opportunities for more LLM-based applications to assist radiologists without requiring full FDA device approval, provided clinicians retain review authority.
- 5Image-analyzing AI (such as CAD or denoising tools) remains regulated as medical devices.
Why It Matters
This policy shift could accelerate development and clinical adoption of text-based AI assistants and reporting tools in radiology, reducing regulatory barriers. Clarity from the FDA also helps innovators and healthcare providers assess which AI-driven software must undergo formal device review.
Source
AuntMinnie
Related News
•AuntMinnie
ONC Official at SIIM Calls for Smarter AI and Better Image Sharing
ONC's Dr. Jason Funderburk urges improvements in medical image sharing and AI readiness at SIIM 2024.
•HealthExec
House Moves to Block AI-Driven Medicare Prior Authorization Pilot
A U.S. House committee voted to block the expansion of an AI-driven Medicare prior authorization pilot active in six states.
•Radiology Business
Navigating Payment and Reimbursement for Radiology AI Solutions
Radiology AI reimbursement in the US remains complex and fragmented, complicating provider and vendor payment strategies.